Phospholipid vesicle-based permeation assay and EpiSkin ® in assessment of drug therapies destined for skin administration

Journal of Pharmaceutical Sciences

Volumn 104, Issue 3, 2015, Pages 1119-1127

  Engesland, Andr É ^a   Škalko Basnet, Nata Š A ^a   Flaten, Gøril Eide ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

EpiSkin ; In vitro; Lipids; Liposomes; Permeability; PVPA; Reconstructed human epidermis; Skin; Transdermal drug delivery

Indexed keywords

ACICLOVIR; CAFFEINE; CERAMIDE; CHLORAMPHENICOL; CHOLESTEROL; CHOLESTEROL SULFATE; LIPOSOME; PALMITIC ACID; POLYSORBATE 80; ARTIFICIAL MEMBRANE; PHOSPHOLIPID;

ARTICLE; ASSAY; CHEMICAL COMPOSITION; CONTROLLED STUDY; COST; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUTION; DRUG STABILITY; EPISKIN; EX VIVO STUDY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIPOPHILICITY; MOLECULAR WEIGHT; PHOSPHOLIPID VESICLE BASED PERMEATION ASSAY; PHYSICAL CHEMISTRY; SKIN; SKIN PENETRATION; STRATUM CORNEUM; TOPICAL DRUG ADMINISTRATION; ANIMAL TESTING ALTERNATIVE; ARTIFICIAL MEMBRANE; ARTIFICIAL SKIN; BIOLOGICAL MODEL; CELL CULTURE; CELL MEMBRANE PERMEABILITY; CHEMISTRY; COMPARATIVE STUDY; CYTOLOGY; INTRADERMAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; METABOLISM; PHARMACEUTICS; PROCEDURES; REPRODUCIBILITY; SKIN ABSORPTION;

ACYCLOVIR; ADMINISTRATION, CUTANEOUS; ANIMAL TESTING ALTERNATIVES; CAFFEINE; CELL MEMBRANE PERMEABILITY; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; CHLORAMPHENICOL; HUMANS; MEMBRANES, ARTIFICIAL; MODELS, BIOLOGICAL; PHOSPHOLIPIDS; REPRODUCIBILITY OF RESULTS; SKIN; SKIN ABSORPTION; SKIN, ARTIFICIAL; TECHNOLOGY, PHARMACEUTICAL;

EID: 84922810636     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24315     Document Type: Article

References (45)

1. Schafer-Korting M, Mehnert W, Korting HC. 2007. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev 59(6):427-443.
2. Palac Z, Engesland A, Flaten GE, Skalko-Basnet N, Filipovic-Grcic J, Vanic Z. 2014. Liposomes for (trans)dermal drug delivery: The skin-PVPA as a novel in vitro stratum corneum model in formulation development. J Liposome Res 24(4):313-322.
3. Barry BW. 2001. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 14(2):101-114.
4. El Maghraby GM, Barry BW, Williams AC. 2008. Liposomes and skin: From drug delivery to model membranes. Eur J Pharm Sci 34(4-5):203-222.
5. El Maghraby GM, Williams AC, Barry BW. 2006. Can drug-bearing liposomes penetrate intact skin? J Pharm Pharmacol 58(4):415-429.
6. Bouwstra JA, Honeywell-Nguyen PL, Gooris GS, Ponec M. 2003. Structure of the skin barrier and its modulation by vesicular formulations. Prog Lipid Res 42(1):1-36.
7. Bouwstra JA, Ponec M. 2006. The skin barrier in healthy and diseased state. Biochim Biophys Acta 1758(12):2080-2095.
8. Oliveira G, Beezer AE, Hadgraft J, Lane ME. 2010. Alcohol enhanced permeation in model membranes. Part I. Thermodynamic and kinetic analyses of membrane permeation. Int J Pharm 393(1-2):61-67.
9. Oliveira G, Beezer AE, Hadgraft J, Lane ME. 2011. Alcohol enhanced permeation in model membranes. Part II. Thermodynamic analysis of membrane partitioning. Int J Pharm 420(2):216-222.
10. Sinko B, Garrigues TM, Balogh GT, Nagy ZK, Tsinman O, Avdeef A, Takacs-Novak K. 2012. Skin-PAMPA: A new method for fast prediction of skin penetration. Eur J Pharm Sci 45(5):698-707.
11. Gregoire S, Patouillet C, Noe C, Fossa I, Benech Kieffer F, Ribaud C. 2008. Improvement of the experimental setup for skin absorption screening studies with reconstructed skin EPISKIN. Skin Pharmacol Physiol 21(2):89-97.
12. Engesland A, Skar M, Hansen T, Skalko-Basnet N, Flaten GE. 2013. New applications of phospholipid vesicle-based permeation assay: Permeation model mimicking skin barrier. J Pharm Sci 102(5):1588-1600.
13. Flaten GE, Dhanikula AB, Luthman K, Brandl M. 2006. Drug permeability across a phospholipid vesicle based barrier: A novel approach for studying passive diffusion. Eur J Pharm Sci 27(1):80-90.
14. Flaten GE, Bunjes H, Luthman K, Brandl M. 2006. Drug permeability across a phospholipid vesicle-based barrier 2. Characterization of barrier structure, storage stability and stability towards pH changes. Eur J Pharm Sci 28(4):336-343.
15. Hansen T, Ausbacher D, Flaten GE, Havelkova M, Strom MB. 2011. Synthesis of cationic antimicrobial beta(2,2)-amino acid derivatives with potential for oral administration. J Med Chem 54(3):858-868.
16. Kanzer J, Tho I, Flaten GE, Magerlein M, Holig P, Fricker G,Brandl M. 2010. In-vitro permeability screening of melt extrudate formulations containing poorly water-soluble drug compounds using the phospholipid vesicle-based barrier. J Pharm Pharmacol 62(11):1591-1598.
17. Naderkhani E, Erber A, Skalko-Basnet N, Flaten GE. 2014. Improved permeability of acyclovir: Optimization of mucoadhesive liposomes using the phospholipid vesicle-based permeation assay. J Pharm Sci 103(2):661-668.
18. Godin B, Touitou E. 2007. Transdermal skin delivery: Predictions for humans from in vivo, ex vivo and animal models. Adv Drug Deliv Rev 59(11):1152-1161.
19. Netzlaff F, Lehr CM, Wertz PW, Schaefer UF. 2005. The human epidermis models EpiSkin, SkinEthic and EpiDerm: An evaluation of morphology and their suitability for testing phototoxicity, irritancy, corrosivity, and substance transport. Eur J Pharm Biopharm 60(2):167-178.
20. Schafer-Korting M, Bock U, Diembeck W, Dusing HJ, Gamer A, Haltner-Ukomadu E, Hoffmann C, Kaca M, Kamp H, Kersen S, Kietzmann M, Korting HC, Krachter HU, Lehr CM, Liebsch M, Mehling A, Muller-Goymann C, Netzlaff F, Niedorf F, Rubbelke MK, Schafer U, Schmidt E, Schreiber S, Spielmann H, Vuia A, Weimer M. 2008. The use of reconstructed human epidermis for skin absorption testing: Results of the validation study. Altern Lab Anim 36(2):161-187.
21. Mathes SH, Ruffner H, Graf-Hausner U. 2014. The use of skin models in drug development. Adv Drug Deliv Rev 69-70:81-102.
22. Alepee N, Grandidier MH, Cotovio J, Organisation for Economic C-o, Development. 2014. Sub-categorisation of skin corrosive chemicals by the EpiSkin reconstructed human epidermis skin corrosion test method according to UN GHS: Revision of OECD Test Guideline 431. Toxicol In Vitro 28(2):131-145.
23. Rozman B, Gasperlin M, Tinois-Tessoneaud E, Pirot F, Falson F. 2009. Simultaneous absorption of vitamins C and E from topical microemulsions using reconstructed human epidermis as a skin model. Eur J Pharm Biopharm 72(1):69-75.
24. Dreher F, Fouchard F, Patouillet C, Andrian M, Simonnet JT, Benech-Kieffer F. 2002. Comparison of cutaneous bioavailability of cosmetic preparations containing caffeine or alpha-tocopherol applied on human skin models or human skin ex vivo at finite doses. Skin Pharmacol Appl Skin Physiol 15(Suppl 1):40-58.
25. United States Pharmacopeia and National Formulary (USP 37-NF 32). 2014. USP monographs: Chloramphenicol. Rockville, MD: United States Pharmacopeial Convention Inc., p 2277.
26. Schafer-Korting M, Mahmoud A, Lombardi Borgia S, Bruggener B, Kleuser B, Schreiber S, Mehnert W. 2008. Reconstructed epidermis and full-thickness skin for absorption testing: Influence of the vehicles used on steroid permeation. Altern Lab Anim 36(4):441-452.
27. Sentjurc M, Vrhovnik K, Kristl J. 1999. Liposomes as a topical delivery system: The role of size on transport studied by the EPR imaging method. J Control Release 59(1):87-97.
28. Cevc G. 1996. Transfersomes, liposomes and other lipid suspensions on the skin: Permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit Rev Ther Drug Carrier Syst 13(3-4):257-388.
29. Gillet A, Compere P, Lecomte F, Hubert P, Ducat E, Evrard B, Piel G. 2011. Liposome surface charge influence on skin penetration behaviour. Int J Pharm 411(1-2):223-231.
30. Pavelic Z, Skalko-Basnet N, Filipovic-Grcic J, Martinac A, Jalsenjak I. 2005. Development and in vitro evaluation of a liposomal vaginal delivery system for acyclovir. J Control Release 106(1-2):34-43.
31. Pavelic Z, Skalko-Basnet N, Jalsenjak I. 2004. Liposomal gel with chloramphenicol: Characterisation and in vitro release. Acta Pharm 54(4):319-330.
32. Netzlaff F, Kaca M, Bock U, Haltner-Ukomadu E, Meiers P, Lehr CM, Schaefer UF. 2007. Permeability of the reconstructed human epidermis model Episkin in comparison to various human skin preparations. Eur J Pharm Biopharm 66(1):127-134.
33. Van Gele M, Geusens B, Brochez L, Speeckaert R, Lambert J. 2011. Three-dimensional skin models as tools for transdermal drug delivery: Challenges and limitations. Expert Opin Drug Deliv 8(6):705-720.
34. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M. 2008. DrugBank: A knowledge base for drugs, drug actions and drug targets. Nucleic Acids Res 36(Database issue):D901-D906.
35. Dreher F, Patouillet C, Fouchard F, Zanini M, Messager A, Roguet R, Cottin M, Leclaire J, Benech-Kieffer F. 2002. Improvement of the experimental setup to assess cutaneous bioavailability on human skin models: Dynamic protocol. Skin Pharmacol Appl Skin Physiol 15(Suppl 1):31-39.
36. Naderkhani E, Isaksson J, Ryzhakov A, Flaten GE. 2014. Development of a biomimetic phospholipid vesicle-based permeation assay for the estimation of intestinal drug permeability. J Pharm Sci 103(6):1882-1890.
37. Flaten GE, Skar M, Luthman K, Brandl M. 2007. Drug permeability across a phospholipid vesicle based barrier: 3. Characterization of drug-membrane interactions and the effect of agitation on the barrier integrity and on the permeability. Eur J Pharm Sci 30(3-4):324-332.
38. Flaten GE, Luthman K, Vasskog T, Brandl M. 2008. Drug permeability across a phospholipid vesicle-based barrier 4. The effect of tensides, co-solvents and pH changes on barrier integrity and on drug permeability. Eur J Pharm Sci 34(2-3):173-180.
39. Fischer SM, Flaten GE, Hagesaether E, Fricker G, Brandl M. 2011. In-vitro permeability of poorly water soluble drugs in the phospholipid vesicle-based permeation assay: The influence of nonionic surfactants. J Pharm Pharmacol 63(8):1022-1030.
40. Svenson J, Karstad R, Flaten GE, Brandsdal BO, Brandl M, Svendsen JS. 2009. Altered activity and physicochemical properties of short cationic antimicrobial peptides by incorporation of arginine analogues. Mol Pharm 6(3):996-1005.
41. Flaten GE, Kottra G, Stensen W, Isaksen G, Karstad R, Svendsen JS, Daniel H, Svenson J. 2011. In vitro characterization of human peptide transporter hPEPT1 interactions and passive permeation studies of short cationic antimicrobial peptides. J Med Chem 54(7):2422-2432.
42. Perlovich GL, Proshin AN, Volkova TV, Petrova LN, Bachurin SO. 2012. Novel 1,2,4-thiadiazole derivatives as potent neuroprotectors: Approach to creation of bioavailable drugs. Mol Pharm 9(8):2156-2167.
43. Fischer SM, Buckley ST, Kirchmeyer W, Fricker G, Brandl M. 2012. Application of simulated intestinal fluid on the phospholipid vesiclebased drug permeation assay. Int J Pharm 422(1-2):52-58.
44. Gantzsch SP, Kann B, Ofer-Glaessgen M, Loos P, Berchtold H, Balbach S, Eichinger T, Lehr CM, Schaefer UF, Windbergs M. 2014. Characterization and evaluation of a modified PVPA barrier in comparison to Caco-2 cell monolayers for combined dissolution and permeation testing. J Control Release 175:79-86.
45. Harvey RD, Ara N, Heenan RK, Barlow DJ, Quinn PJ, Lawrence MJ. 2013. Stabilization of distearoylphosphatidylcholine lamellar phases in propylene glycol using cholesterol. Mol Pharm 10(12):4408-4417.